Office-Based Opioid Treatment
Prescriber and Dispensing Site Regulations
Quick Reference Guide (6.14.21/3.3)

OBOT professional services and medications are covered when provided by primary care or specialty medical/psychiatric providers, including physicians (MD or DO), advanced practice registered nurse practitioners (APRN or NP), and physician assistants (PA) when the service has been delegated by a supervising physician.

**OBOT Prescriber Regulations**

Prescribing buprenorphine products for OUD requires the prescribing clinician to have a Drug Addiction Treatment Act of 2000 (DATA 2000) waiver and obtain a Delaware Controlled Substance Registration (CSR).\(^1\) Prior to April 28, 2021, MOUD prescribers were required to take a specialized training and certify their capacity to provide counseling and ancillary services to receive the DATA 2000 waiver. However, on April 28, 2021, the Department of Health and Human Services released new Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder waiving certain requirements for prescribing clinicians to treat up to 30 patients. These clinicians can receive their DATA 2000 waiver by submitting a “Notice of Intent” to the Substance Abuse and Mental Health Services Administration and are not required to participate in specialized waiver training or certify their capacity to provide counseling and ancillary services. Prescribers who do not wish to practice under this exemption and its attendant 30 patient limit may seek a waiver per established protocols. If prescribers intend to dispense MOUDs on site, there are subject to additional requirements identified below.

**OBOT Dispensing Site Regulations**

In addition to the prescriber regulations referenced above, each Delaware practice location that dispenses/stores medications for opioid use disorder must have a Delaware Controlled Substance Registration tied to that specific location. As such, if no other prescriber holds a Delaware CSR for a location where controlled substances will be stored/dispensed, the prescribing/dispensing prescriber must apply for an additional CSR for that location.

For more information, please visit [https://dpr.delaware.gov/boards/controlledsubstances/faqs/](https://dpr.delaware.gov/boards/controlledsubstances/faqs/).

---

\(^1\) [https://dpr.delaware.gov/boards/controlledsubstances/faqs/](https://dpr.delaware.gov/boards/controlledsubstances/faqs/); APRNs and PAs must have a license with prescriptive authority before a CSR application will be processed. Prescribers need only one Delaware CSR to prescribe controlled substances in Delaware even if prescribing controlled substances at more than one Delaware location of a business/practice.

This is intended as quick reference guide and up to date as of June 14, 2021. Policy is subject to change and formal DMMA policy documents supersedes any information in this quick reference guide. This project is supported by the Centers for Medicare and Medicaid Services (CMS) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $3,693,864 with 100 percent funded by CMS/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by CMS/HHS, or the U.S. Government.